In this multicenter, phase II, single-arm study, 52 patients with recurrent or metastatic HER2-positive (D) breast cancer received first-line eribulin with trastuzumab. The objective response rate (ORR) was 71.2% (n [ 37) with a median time to first response (TTR) of 1.3 months; duration of response (DOR) and progressionfree survival (PFS) were 11.1 and 11.6 months, respectively. Eribulin/trastuzumab combination resulted in a substantial tumor response with an acceptable safety profile. Background: The aim of this study was to assess efficacy and safety of eribulin with trastuzumab as first-line therapy for locally recurrent or metastatic HER2þ breast cancer. Patients and Methods: In this multicenter, phase II, singlearm study, patients with recurrent or metastatic HER2þ breast cancer received eribulin mesylate at 1.4 mg/m 2 intravenously (I.V.) on days 1 and 8 of each 21-day cycle with an initial trastuzumab dose of 8 mg/kg I.V. on day 1, followed by 6 mg/kg of trastuzumab on day 1 of each subsequent cycle. Tumor assessments were conducted every 6 weeks for the first 6 cycles and every 12 weeks thereafter. The primary end point was ORR, and secondary end points included PFS, TTR, DOR, and safety. Results: Fifty-two patients were enrolled. Fifty-one patients (98.1%) had metastatic disease, 25 (48.1%) with liver metastases, 24 (46.2%) with lung metastases, and 19 (36.5%) with bone metastases. Patients received a median of 10.0 cycles of eribulin and 11.0 cycles of trastuzumab. The ORR was 71.2% (n ¼ 37) with median TTR of 1.3 months, DOR of 11.1 months, and PFS of 11.6 months. The most common Grade 3/4 treatment-emergent adverse events were neutropenia in 20 (38.5%) patients, peripheral neuropathy in 14 (26.9%; all Grade 3) patients, fatigue in 4 (7.7%) patients, and febrile neutropenia in 4 (7.7%) patients. Conclusions: Because of the high ORR, prolonged median PFS, and acceptable safety profile, combination eribulin/trastuzumab is an acceptable treatment option for locally recurrent or metastatic HER2þ breast cancer.
Introduction
In the United States, approximately 5% to 10% of all women have metastatic breast cancer (MBC) at the time of initial diagnosis. 1, 2 The prognosis for these patients is poor, with an estimated 5-year survival rate of 24.3%. 1 In a recent survey of 107 published studies involving 39,730 patients, the overall rate of breast cancer with tumors positive for the transmembrane tyrosine kinase receptor was 22.2% (range, 9%-74%). 3 In addition, the frequency of HER2-positivity is increased among patients with metastatic disease. 4 Trastuzumab, a humanized monoclonal antibody directed against the extracellular domain of HER2, 5 combined with recently approved pertuzumab, is recommended as part of first-line therapy for women with HER2-positive (þ) tumors and metastatic disease. 6 Results from multiple clinical trials have demonstrated that the combination of trastuzumab and pertuzumab with any of several conventional chemotherapeutic agents, including carboplatin, docetaxel, vinorelbine, paclitaxel, or capecitabine, is effective for the treatment of HER2-overexpressing metastatic breast cancer (MBC). [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Eribulin mesylate is a nontaxane inhibitor of microtubule dynamics in the halichondrin class of antineoplastic drugs. [18] [19] [20] [21] Specifically, eribulin is a microtubule inhibitor that is a structurally modified synthetic analogue of halichondrin B. 18 Eribulin has a novel mode of action that is distinct from those of other tubulintargeting agents; it only binds to the growing positive ends, inhibiting the microtubule growth phase without affecting the shortening phase and causing tubulin sequestration into nonproductive aggregates. [18] [19] [20] [21] This unique tubulin-based mechanism of action might explain how eribulin is able to overcome taxane resistance and have potentially a wider clinical effect. 22 Approval of eribulin in the United States, European Union, Japan, and other countries was based on the Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389 (EMBRACE), a phase III open-label study in which women with locally recurrent or metastatic breast cancer were randomly allocated (2:1) to eribulin mesylate or treatment of physician's choice. 23 The phase III EMBRACE study showed significant improvements in overall survival with eribulin versus treating physician's choice of therapy (most often including vinorelbine, gemcitabine, or capecitabine) in previously treated women with MBC. Results from EMBRACE also indicated that the safety and tolerability of eribulin were similar to those for the other chemotherapeutic agents used in the study, and that rates of peripheral neuropathy for eribulin and taxanes were 35% and 45%, respectively. In addition, the authors of the EMBRACE study noted that eribulin has a short infusion time and requires no premedication to prevent hypersensitivity. 23 Because of its antitumor activity in the challenging setting of lateline treatment, infusion time (1.4 mg/m 2 intravenous [I.V.] over 2-5 minutes on days 1 and 8 of a 21-day cycle), and no premedication requirement to prevent hypersensitivity, assessment of eribulin in the first-line setting for women with MBC is warranted. 23, 24 The objective of this phase II trial was to assess the antitumor activity and safety of eribulin in combination with trastuzumab as first-line therapy for patients with locally recurrent or metastatic HER2þ breast cancer.
Patients and Methods

Study Design
In this multicenter, single-arm, phase II trial, we assessed the objective response rate (ORR) of eribulin in combination with trastuzumab in patients with locally recurrent (regardless of resectability) or metastatic HER2þ breast cancer. The study had 3 phases: screening and baseline, six 21-day cycles of eribulin with trastuzumab, and an extension phase in which patients who completed the initial 6 cycles continued to receive study treatment until the development of progressive disease (PD) or until another withdrawal criterion was met.
The study was conducted in accordance with the Declaration of Helsinki (2008) , and the protocol and informed consent forms were submitted for approval to institutional review boards by the primary investigators. All patients provided written informed consent before undergoing any study-related procedures.
Patients
Women ! 18 years of age were eligible for inclusion if they met the following criteria: histologically or cytologically proven recurrent or metastatic adenocarcinoma of the breast with at least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; a HER2þ tumor determined by a score of 3þ on immunohistochemistry staining or gene amplification by fluorescence in situ hybridization; life expectancy of ! 24 weeks; Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2; ! 12 months since previous neoadjuvant or adjuvant chemotherapy (no washout period for previous adjuvant trastuzumab); ! 2 weeks since previous radiotherapy or endocrine therapy, trastuzumab, or lapatinib, with complete recovery from the effects of these interventions; and adequate renal, bone marrow, liver, and cardiac function. Previous hormonal therapy was allowed.
Patients were excluded if they had received previous chemotherapy, biologic therapy, or investigational therapy for locally recurrent or metastatic HER2þ breast cancer; had previous exposure of > 360 mg/m 2 
Concomitant Medications
Any medication that was considered necessary for the patient's welfare and was not expected to interfere with the evaluation of study treatment could be given at the discretion of the investigator. This included granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and erythropoietin, administered according to American Society of Clinical Oncology guidelines and standard practice; stable bisphosphonate doses; and palliative radiotherapy (< 10% of bone marrow). Other antitumor therapies were not permitted.
End Points
Baseline tumor assessments (computed tomography or magnetic resonance imaging scans) of the chest, abdomen, pelvis, and other areas of known disease were performed within 28 days before the first infusion of study treatment, every 6 weeks during the treatment phase, and every 12 weeks in the extension phase. The primary end point was antitumor activity of eribulin with trastuzumab assessed by determining ORR-based investigator review using RECIST 1.1. The ORR was defined as the proportion of subjects who achieved a complete response (CR) plus those who achieved a partial response (PR). To be assigned a status of PR or CR, changes in tumor measurements must have been confirmed in repeat evaluations carried out ! 4 weeks after the response criteria were first met. Secondary end points included time to first response (TTR) and duration of response (DOR) for patients whose best overall response was CR or PR and progression-free survival (PFS). Quality of life (QoL) was assessed using the European Organisation for Research and Treatment of Cancer QoL assessment tool (QLQ-C30) and breast module BR23 at screening or baseline, every other cycle during the study, and end-of-treatment visit; results are forthcoming and will be presented in a future analysis.
Safety and Tolerability
Safety parameters included adverse events (AEs) and serious AEs (SAEs); hematology and clinical chemistry; physical examinations; periodic measurement of vital signs and electrocardiograms (ECGs); and evaluation of left ventricular ejection fraction (LVEF) using multigated acquisition scans or echocardiograms and were assessed at baseline, every fourth treatment cycle, and at the endof-treatment visit. AEs had to occur after and not before dosing of study treatment. All AEs were followed until resolution or for 30 days after the subject's last study visit. However, treatmentemergent peripheral neuropathy and alopecia of any grade were followed until resolution or until another anticancer therapy was started. AEs were graded on a 5-point scale according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
Statistical Analysis
All efficacy analyses were based primarily on the full analysis set, which included all patients who received ! 1 dose of study treatment. Baseline demographic and clinical characteristics were summarized. The ORR was determined along with corresponding 2-sided, exact binomial 95% confidence intervals (CIs). TTR, DOR, and PFS were analyzed using Kaplan-Meier product-limit estimates. Disease control rate (DCR; CR þ PR þ stable disease), clinical benefit rate (CBR; CR þ PR þ stable disease ! 6 months), and 95% CIs were also determined. For PFS subgroup analysis, 95% CIs were calculated; because of the small sample size, no covariate adjustment was made in the analysis.
Results
Patient Characteristics
A total of 52 patients (median age of 59.5 years), 51 (98.1%) with metastatic disease, entered the study; 45 patients completed the treatment phase (the first 6 cycles of treatment) and 9 discontinued because of AEs (n ¼ 3), PD (n ¼ 3), or other reasons (n ¼ 3; Table 1 ). Eight patients were still in the extension phase of the treatment at the time of clinical data cut. Median daily intensity was 0.13 mg/m 2 /d (minimum, 0.1; maximum, 1.4) per patient.
Mean number of eribulin doses was 23.8 and the median number of cycles received per patient was 10.0 (range, 0-38) for eribulin and 11.0 (range, 1-37) for trastuzumab. No patient received palliative radiotherapy during the study.
Efficacy
Overall, 52 patients in the full analysis set were evaluable for ORR ( Table 2 ). The ORR was 71.2% (n ¼ 37; 95% CI, The median PFS was 11.6 months (95% CI, 9.1-13.9; Figure 2 ) and Kaplan-Meier estimates for the 3-, 6-, 9-, and 12-month PFS rates were 96%, 82%, 67%, and 49%, respectively. Forest plot of PFS subgroup analyses are included in Figure 3 . Factors associated with a shorter PFS (> 2-month reduction in PFS vs. the overall median value) were patients with hormone-negative disease (9.5 months; n ¼ 15); estrogen receptor-positive/progesterone receptor-positive (9.2 months; n ¼ 21); baseline ECOG status 1 or 2 (9.2 months; n ¼ 15); < 2 years from adjuvant or neoadjuvant therapy to start of current treatment (5.0 months; n ¼ 6); MBC diagnosed within 3 months of original diagnosis (9.5 months; n ¼ 20); liver involvement (9.5 months; n ¼ 25); and metastases involving 2 organs (9.2 months; n ¼ 24). PFS was extended by > 2 months versus the overall median value in metastases involving the number of target lesions (> 3) (13.9 months; n ¼ 6); however, these subgroups are small, and therefore results should be interpreted with caution.
Safety
All patients reported treatment-emergent AEs (TEAEs), and all reported TEAEs that were considered to be related to either eribulin or trastuzumab (Table 3) 
The most common TEAEs (all grades occurring in ! 50% of patients) were alopecia (88.5%; n ¼ 46), fatigue (69.2%; n ¼ 36), neutropenia (59.6%; n ¼ 31), and peripheral neuropathy (69.2%; n 
Treatment-emergent AEs led to dose adjustment (interruption/ delay, reduction, or discontinuation/withdrawal) of either eribulin, trastuzumab, or both, in 36 (69.2%) patients. Specifically, TEAEs led to withdrawal of 1 or both study drugs in 11 (21.2%) patients, dose reduction in 21 (40.4%) patients, and study drug interruption in 22 (42.3%) patients. Peripheral neuropathy led to discontinuations in 7 (13.5%) patients, dose reduction in 10 (19.2%) patients, and dose interruption in 5 (9.6%) patients. Neutropenia led to dose reductions in 6 (11.5%) patients and dose interruptions in 11 (21.2%) patients, but it did not lead to any discontinuations. Serious TEAEs occurred in 15 patients (28.8%). Neutropenia (all Grades) occurred in 8 (15.4%) patients, febrile neutropenia (all Grades) in 4 (7.7%), peripheral neuropathy (SMQ term) in 4 (7.7%), and vomiting in 3 (5.8%). There was 1 death during the study. A 59-year-old white patient died from chronic heart failure 15 days after her last dose of study treatment, after a total treatment duration of 274 days. At baseline, the patient was receiving amlodipine, furosemide, atorvastin, losartan, and atenolol, and medications for diabetes. Medical and surgical history included arteriosclerosis of the coronary artery, coronary artery bypass, diabetes mellitus, hyperlipidemia, and hypertension. The patient had NYHA Class I, ECOG was 0, and her LVEF values at baseline were normal. Her LVEF evaluations at screening, baseline, and cycle 12, day 1 were 71%, 71%, and 55%, respectively. The patient did not meet the criteria for exclusion which were clinically significant cardiovascular impairment (ie, history of congestive heart failure greater than NYHA Class II, unstable/active angina or myocardial infarction 6 months before day 1 of this study, or 20 24
Abbreviation: NE ¼ not estimable. 
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Clinical Breast Cancer December 2014 -409 serious cardiac arrhythmia). The death was considered to be possibly related to the study drug by the treating investigator. Grade 3/4 clinical laboratory hematologic abnormalities included leukocytes (23.1%; n ¼ 12), neutrophils (55.8%; n ¼ 29), and lymphocytes (2.2%; n ¼ 1). Grade 3/4 clinical chemistry abnormalities included increases in alanine aminotransferase (2.0%; n ¼ 1), sodium (3.8%; n ¼ 2), potassium (3.8%; n ¼ 2), phosphorus (4.0%; n ¼ 2), and calcium (1.9%; n ¼ 1).
One subject (1.9%) with normal baseline ECG and 3 subjects (5.8%) with clinically nonsignificant abnormal ECG findings at baseline had clinically significant abnormal findings during the study. The median change from baseline to end of treatment for LVEF was À5.0%. The 3 patients with Grade 2 LVEF decrease had trastuzumab dose delay.
Discussion
The results of this phase II trial suggest the combination of eribulin with trastuzumab has considerable activity with an acceptable toxicity profile as first-line therapy for HER2þ locally advanced or metastatic breast cancer. Results for the 52 patients evaluated in this phase II, single-arm study indicated ORR in 37 (71.2%) patients. The median DOR was 11.1 months and the median PFS was 11.6 months. The most common Grade 3/4 TEAEs (occurring in ! 5% of patients) were neutropenia (38.5%; n ¼ 20), peripheral neuropathy (26.9%; n ¼ 14, all Grade 3 [SMQ]), fatigue (7.7%; n ¼ 4), febrile neutropenia (7.7%; n ¼ 4), vomiting (5.8%; n ¼ 3), leucopenia (5.8%; n ¼ 3), and hyperglycemia (5.8%; n ¼ 3).
Guidelines currently recommend pertuzumab with trastuzumab in combination with a taxane as a preferred option for first-line treatment of patients with HER2þ MBC. 6 Other first-line treatment regimens for HER2þ tumors include HER2þ blockading treatments such as trastuzumab with chemotherapy. 6 The activity demonstrated for eribulin with trastuzumab as first-line treatment for women with HER2þ locally advanced or metastatic breast cancer in the present study appears comparable with that reported for other chemotherapy combinations evaluated in this setting. Along with lapatinib, 4 chemotherapeutic agents are currently recommended in combination with trastuzumab as first-line treatment for patients with HER2þ MBC: docetaxel, vinorelbine, capecitabine, and paclitaxel with or without carboplatin. 6 Results for trastuzumab with docetaxel have indicated PFS ranging from 8.3 to 12.4 months and ORR ranging from 45% to 64%. [25] [26] [27] [28] Results for vinorelbine with trastuzumab are generally similar to those that have been reported for docetaxel. One study that compared vinorelbine combined with trastuzumab and docetaxel combined with trastuzumab reported PFS of 15.3 and 12.4 months, respectively, and an ORR of 59.3% in both arms. 27 A second study that combined oral or I.V. vinorelbine with trastuzumab reported PFS of 9.3 months and an ORR of 70.3%. 7 The combination of trastuzumab and capecitabine has been shown to result in PFS of 7.8 to 9.3 months and an ORR of 38% to 65% in patients with HER2þ MBC. 10, 29 Results for the combination of trastuzumab and paclitaxel indicated PFS ranging from 7.1 to 12.3 months and ORR of 36% to 75%. [30] [31] [32] A PFS of 10.7 months and an ORR of 52% have been reported for the combination of trastuzumab with paclitaxel and carboplatin. 32 The activity of eribulin with trastuzumab appears comparable with that of other combinations currently recommended for HER2þ MBC. Although incidence rates vary, peripheral neuropathy is a common AE in patients treated with microtubule-targeted agents occurring in up to 30% of patients. 33 Peripheral neuropathy Grade 3/4 also occurs frequently in patients treated with eribulin. In the phase 3 EMBRACE trial, 35% of eribulin-treated patients had neuropathy, but < 9% had Grade 3/4 neuropathy. 23 In the present study, 36 (69.2%) patients experienced neuropathy, and 14 (26.9%) experienced Grade 3 neuropathy; no Grade 4 neuropathy was observed. This higher rate of Grade 3 neuropathy was likely due to the prolonged duration of eribulin treatment in this first-line setting.
In phase II and III trials in which patients with HER2þ MBC received microtubule-targeting agents as first-line treatment, rates of Grade 3/4 febrile neutropenia ranged from 10.1% to 37.4%. 27 Robert et al reported 27% of patients receiving trastuzumab and paclitaxel and 57% receiving carboplatin with trastuzumab and paclitaxel reported Grade 3/4 neutropenia. 32 In the current trial, all Grades of febrile neutropenia and neutropenia occurred in 4 (7.7%) and 31 (59.6%) patients and Grade 3/4 was reported in 4 (7.7%) and 20 (38.5%) patients, respectively. The duration of treatment (patients received 10.0 cycles [median] of eribulin treatment) could have contributed to cumulative neuropathic toxicity; notably, the median time to onset of treatment-emergent Grade 3/4 peripheral neuropathy was 568 days and the median duration of treatment-emergent peripheral neuropathy was 155 days for any Grade and 23 days for Grade 3/4. Although dose reductions were caused mostly by neutropenia and peripheral neuropathy, patients who received a modified dose achieved greater tumor response rates (ie, ORR, DCR, CBR, and durable stable disease) compared with those who did not. Thus, patients continued to derive clinical benefit from eribulin regardless of whether dose was reduced or maintained.
25-28
A recent systematic review of clinical studies of patients with MBC indicated that Grade 3/4 peripheral sensory neuropathy might occur in as many as 30.9% of patients treated with docetaxel and 33% of those treated with paclitaxel. 34 Analysis of phase II/III studies of ixabepilone in patients with pretreated MBC indicated that Grade 3/4 peripheral sensory neuropathy might occur in approximately 20% of patients. 35 The suggested clinical differences between eribulin and other microtubule-targeted agents are consistent with results from an experimental animal study that indicated eribulin had no effects on caudal and digital nerve conduction velocity and amplitude, compared with significant reductions in both of these measures with paclitaxel and ixabepilone. Eribulin caused mild changes in the structure of the sciatic nerve and dorsal root ganglion cells, compared with moderate-to-severe degenerative changes for paclitaxel and ixabepilone. 36 Neuropathic symptoms resulting from treatment can cause treatment delays, dose reductions, or even discontinuation of therapy, and reduced QoL, and might interfere with activities of daily living, all of which can affect outcomes and compromise survival. 37 Although rigorous studies on the assessment, prevention, and management of cancer treatment-related neuropathy are limited, guidelines suggest that physicians actively query cancer patients on signs and symptoms of neuropathy, especially considering that underestimation and underreporting of symptoms is common. 37 Patient history should include associated comorbidity, including inquiring about diabetes history or history of sensory neuropathy, personal and family history of neuropathy, alcohol use and other toxic exposures, and any neuropathy experienced during previous treatment. 37 A detailed treatment profile should be described (regimen dosage, duration, schedule, coasting), and the characteristics and distribution of signs and symptoms. 37 Recommended physician-based grading systems include the National Cancer Institute CTCAE, 38 Ajani Sensory, 39 World Health Organization, 40 and ECOG systems. 41 Because neuropathy often progresses with dose accumulation, early reporting of mild cases is important when detecting the onset of neuropathy during continuous monitoring. 37 To that end, guidelines recommend using the following pain assessment tools to assess neuropathic symptoms: Brief Pain Inventory, 42, 43 Neuropathic Pain Scale, 44, 45 and Leeds Assessment of Neuropathic Symptoms and Signs Pain Scale, 46, 47 for the identification and assessment of functional deficits associated with neuropathy. 37 
Conclusion
In this multicenter, phase II, single-arm study, the efficacy and safety of eribulin with trastuzumab as first-line therapy for HER2þ MBC were assessed in 52 patients and showed an ORR of 71.2% (n ¼ 37), DOR of 11.1 months, and a median PFS of 11.6 months. The most common Grade 3/4 TEAEs (occurring in ! 5% of patients) were neutropenia (38.5%; n ¼ 20), peripheral neuropathy (21.2%, n ¼ 11; all Grade 3), fatigue (7.7%; n ¼ 4), febrile neutropenia (7.7%; n ¼ 4), vomiting (5.8%; n ¼ 3), leucopenia (5.8%; n ¼ 3), and hyperglycemia (5.8%; n ¼ 3).
The combination of eribulin with trastuzumab as first-line therapy for HER2þ MBC resulted in higher objective response and CBRs, and a prolonged median PFS with an acceptable safety profile similar to other single agents that have been commonly combined with trastuzumab as first-line therapy. Combined eribulin and trastuzumab is an acceptable treatment option for patients with HER2þ MBC.
Clinical Practice Points
The prognosis for patients with MBC at initial diagnosis is poor, with an estimated 5-year survival rate of 24.3%. 1 Approximately 22% (range, 9%-74%) of patients with breast cancer have tumors that are positive for HER2, 3 and the frequency of HER2-positivity is increased among patients with metastatic disease. 4 The EMBRACE study demonstrated improved survival and acceptable tolerability after eribulin treatment for advanced breast cancer in patients with at least 2 previous therapies. 23 Eribulin has a short infusion time and requires no premedication to prevent hypersensitivity. 23 Assessment of eribulin in the first-line setting for women with MBC was warranted, because of its ease of use and its antitumor activity in the challenging setting of late-line treatment. The objective of this phase 2 trial was to assess the antitumor activity and safety of eribulin in combination with trastuzumab as first-line therapy for patients with locally recurrent or metastatic HER2þ breast cancer.
Results for the 52 patients evaluated in this phase II, singlearm study indicated ORR in 71.2%. The median DOR was 11.1 months and the median PFS was 11.6 months. The most common Grade 3/4 TEAEs (occurring in ! 5% of patients) were neutropenia (38.5%), peripheral neuropathy (21.2%, all Grade 3), fatigue (7.7%), febrile neutropenia (7.7%), vomiting (5.8%), hyperglycemia (5.8%), and leucopenia (5.8%).
The results presented here suggest the combination of eribulin with trastuzumab has considerable activity with an acceptable toxicity profile as first-line therapy for HER2þ locally advanced or metastatic breast cancer.
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